SUBSCRIBE
SUBSCRIBE
News   Business

GlaxoSmithKline (JOBS), Vernalis PLC Sign up to $200 Million Cancer Deal

August 6, 2009 | 
1 min read
Bookmark and Share

Reuters -- GlaxoSmithKline Plc, the world's second-largest drugmaker, has signed a deal potentially worth $200 million with British biotech company Vernalis Plc (VER.L) to boost its early-stage research in cancer.
Alliances
GlaxoSmithKline
MORE ON THIS TOPIC
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Century Halves Headcount to ‘Right Size’ Operations
July 10, 2025
 · 
155 min read
 · 
BioSpace Editorial Staff
Fund raising Capital Donation. Funds Support Concept. Fundraising. Collecting donations in jar.
Series B
Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
 · 
1 min read
 · 
Dan Samorodnitsky